Vectibix is used in the treatment of metastatic colorectal cancer (cancer of the bowel) for adult patients with a certain type of tumor known as a “Wild-type RAS tumor”.
Vectibix is used alone or in combination with other anticancer medicines.
Vectibix contains the active substance panitumumab, which belongs to a group of medicines called monoclonal antibodies.Monoclonal antibodies are proteins, which specifically recognize and attach (bind) to other unique proteins in the body.
Panitumumab recognizes and binds specifically to a protein known as epidermal growth factor receptor (EGFR), which is found on the surface of some cancer cells.
When growth factors (other body proteins) attach to the EGFR, the cancer cell is stimulated to grow and divide. Panitumumab binds onto the EGFR and prevents the cancer cell from receiving the messages it needs for growth and division.